American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FARMINGDALE, N.Y., Feb. 27, 2018 -- Misonix, Inc. (Nasdaq:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Canaccord Genuity Musculoskeletal Conference held at the Sheraton hotel in New Orleans, Louisiana on Tuesday, March 6, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 2:30 p.m. CT (3:30 p.m. ET) that day and will be available to meet with institutional investors in one-on-one meetings throughout the day.
The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at [email protected].
About Misonix, Inc.
Misonix, Inc. (Nasdaq:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.
Contact:
Joe Dwyer
Chief Financial Officer
Misonix, Inc.
631-927-9113
Joseph Jaffoni, Norberto Aja, Jennifer Neuman
JCIR
212-835-8500 or [email protected]
